↑ 疾患リストへ ← 戻る

 248. グルコーストランスポーター1欠損症 [臨床試験数:18,薬物数:7(DrugBank:1),標的遺伝子数:0,標的パスウェイ数:0] 

Searched query = "Glucose transporter type 1 deficiency", "GLUT1 deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03301532June 5, 201811 November 2019Compatibility of C7 With Ketogenic Diet in Patients Diagnosed With G1DCompatibility of Triheptanoin (C7) With the Ketogenic Diet in Patients Diagnosed With Glucose Transporter Type 1 DeficiencyGLUT1DS1Drug: TriheptanoinUniversity of Texas Southwestern Medical CenterNational Institute of Neurological Disorders and Stroke (NINDS)Recruiting30 Months35 YearsAll15Early Phase 1United States
2NCT03181399April 18, 201826 August 2019Diet Treatment Glucose Transporter Type 1 Deficiency (G1D)Dietary Treatment of Glucose Transporter Type 1 Deficiency (G1D)GLUT1DS1;Epilepsy;Glut1 Deficiency Syndrome 1, Autosomal Recessive;Glucose Metabolism Disorders;Glucose Transport Defect;Glucose Transporter Type 1 Deficiency Syndrome;Glucose Transporter Protein Type 1 Deficiency SyndromeDrug: TriheptanoinUniversity of Texas Southwestern Medical CenterNational Institute of Neurological Disorders and Stroke (NINDS)Recruiting24 Months35 YearsAll45Phase 2United States
3NCT03202108August 3, 201716 December 2017Evaluation of Krio in Children and Adults With EpilepsyA Feasibility Study to Evaluate the Acceptability of Krio, a Food for Special Medical Purposes (FSMP) for Use in the Ketogenic Diet (KD) With Regard to Product Tolerance, Compliance and AcceptabilityKetogenic Dieting;Epilepsy;Glucose Transporter Type 1 Deficiency SyndromeDietary Supplement: KrioVitaflo International, LtdNot recruiting3 YearsN/AAll15N/AUnited Kingdom
4NCT02968953June 21, 201725 February 2019Treatment With UX007 for a Single Patient With GLUT1 Deficiency SyndromeTreatment With UX007 (Triheptanoin) for a Single Patient (ERS) With Glucose Transporter 1 (GLUT1) Deficiency SyndromeGlucose Transporter 1 Deficiency SyndromeDrug: TriheptanoinJerry Vockley, MD, PhDUltragenyx Pharmaceutical IncNot recruiting3 YearsN/AFemalePhase 2United States
5EUCTR2015-000389-69-ES22/05/201728 February 2019A trial to assess the long term safety and efficacy of UX007 in subjects who have already participated in a UX007 study.An Open-label Extension Study to Assess the Long-term Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type 1 Deficiency SyndromeGlucose Transporter Type 1 deficiency syndrome
MedDRA version: 19.1 Level: LLT Classification code 10061032 Term: Carbohydrate transport disorder System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Triheptanoin
Product Code: UX007
Pharmaceutical Form: Oral solution
INN or Proposed INN: no disponible
CAS Number: 620-67-7
Current Sponsor code: UX007
Other descriptive name: TRIHEPTANOINA
Concentration unit: g/ml gram(s)/millilitre
Concentration type: equal
Concentration number: 96-
Ultragenyx Pharmaceutical IncNot Recruiting Female: yes
Male: yes
40Phase 2France;United States;Spain;Denmark;Australia;Israel;Italy;United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2015-005536-17-DE17/05/201730 April 2019A trial to assess the safety and efficacy of UX007 in patients with movement disorders associated with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)A Phase 3, randomized, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of UX007 in the treatment of movement disorders associated with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)Glucose Transporter Type 1 deficiency syndrome
MedDRA version: 20.0 Level: LLT Classification code 10061032 Term: Carbohydrate transport disorder System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: UX007
Product Code: UX007
Pharmaceutical Form: Oral solution
INN or Proposed INN: Not available
CAS Number: 620-67-7
Current Sponsor code: UX007
Other descriptive name: TRIHEPTANOIN
Concentration unit: g/ml gram(s)/millilitre
Concentration type: equal
Concentration number: 0.96-
Pharmaceutical form of the placebo: Oral solution
Route of administration of the placebo: Oral use
Ultragenyx Pharmaceutical IncNot Recruiting Female: yes
Male: yes
40Phase 3France;United States;Spain;Australia;Israel;Germany;Italy;United Kingdom
7NCT02960217April 19, 20174 November 2019Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)A Phase 3, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)Drug: Placebo;Drug: UX007Ultragenyx Pharmaceutical IncNot recruiting6 YearsN/AAll44Phase 3United States;France;Germany;Italy;Spain;United Kingdom;Israel
8NCT03041363March 29, 201726 August 2019Treatment Development of Triheptanoin (G1D)Treatment Development of Triheptanoin (C7) for Glucose Transporter Type I Deficiency (G1D): A Phase I Maximum Tolerable Dose TrialEpilepsy;GLUT1DS1;Glut1 Deficiency Syndrome 1, Autosomal Recessive;Glucose Metabolism Disorders;Glucose Transport Defect;Glucose Transporter Type 1 Deficiency Syndrome;Glucose Transporter Protein Type 1 Deficiency SyndromeDrug: TriheptanoinUniversity of Texas Southwestern Medical CenterNational Institute of Neurological Disorders and Stroke (NINDS)Not recruiting2 Years35 YearsAll36Phase 1United States
9EUCTR2015-005536-17-ES17/03/20173 April 2017A trial to assess the safety and efficacy of UX007 in patients with movement disorders associated with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)A Phase 3, randomized, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of UX007 in the treatment of movement disorders associated with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)Glucose Transporter Type 1 deficiency syndrome
MedDRA version: 19.1 Level: LLT Classification code 10061032 Term: Carbohydrate transport disorder System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: UX007
Product Code: UX007
Pharmaceutical Form: Oral solution
INN or Proposed INN: Not available
CAS Number: 620-67-7
Current Sponsor code: UX007
Other descriptive name: TRIHEPTANOIN
Concentration unit: g/ml gram(s)/millilitre
Concentration type: equal
Concentration number: 0.96-
Pharmaceutical form of the placebo: Oral solution
Route of administration of the placebo: Oral use
Ultragenyx Pharmaceutical IncAuthorisedFemale: yes
Male: yes
40Phase 3United Kingdom;Italy;Germany;Netherlands;Israel;Australia;Ireland;Spain;United States;France
10NCT02915211April 20163 October 2016Evaluation of Keyo in Children With EpilepsyA Feasibility Study to Evaluate the Acceptability of Keyo, a Food for Special Medical Purposes (FSMP) for Use in the Ketogenic Diet (KD) With Regard to Product Tolerance, Compliance and AcceptabilityIntractable Epilepsy;Glucose Transporter Type 1 Deficiency Syndrome;Ketogenic DietingDietary Supplement: KeyoVitaflo International, LtdNot recruiting3 YearsN/ABoth17N/AUnited Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT02021526December 201525 February 2019Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D)Treatment Development of Triheptanoin for Glucose Transporter Type I DeficiencyGlucose Transporter Type 1 Deficiency Syndrome;Glut1 Deficiency SyndromeDrug: TriheptanoinJuan PascualNot recruiting30 Months55 YearsAll0Phase 1/Phase 2United States
12NCT02599961September 20154 November 2019Study to Assess the Long Term Safety and Efficacy of UX007 in Subjects With Glucose Type 1 DSAn Open-label Extension Study to Assess the Long-term Safety and Efficacy of UX007 in Subjects With Glucose Transporter Type 1 Deficiency SyndromeGlucose Transporter Type 1 Deficiency SyndromeDrug: UX007Ultragenyx Pharmaceutical IncNot recruiting1 YearN/AAll15Phase 2United States;Australia;Denmark;Spain;United Kingdom
13NCT01993186April 20143 September 2018Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study to Assess the Safety and Efficacy of UX007 in Subjects With Glucose Transporter Type 1 Deficiency SyndromeGlucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)Drug: UX007 (triheptanoin);Drug: Placebo OilUltragenyx Pharmaceutical IncNot recruiting1 Year100 YearsAll36Phase 2United States;Australia;France;Israel;Italy;Spain;United Kingdom;Hungary
14NCT02000960April 201413 June 2016Pilot Study of Triheptanoin in Patients With Glucose Transporter 1 Deficiency SyndromeA Controlled N-of-1 Before-and-after Study to Determine Safety and Efficacy Triheptanoin in Patients With Glucose Transporter 1 Deficiency SyndromeGlucose Transporter Type 1 Deficiency SyndromeDrug: TriheptanoinUniversity of British ColumbiaUltragenyx Pharmaceutical IncNot recruiting1 Year18 YearsBoth3Phase 2Canada
15NCT02018302January 201429 April 2019Post Study Continuation of C7 for G1DPost Study Continuation of C7 for G1DGlut1 Deficiency Syndrome;Glucose Transporter Type 1 Deficiency SyndromeDrug: TriheptanoinJuan PascualNot recruiting1 Month28 YearsAllPhase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT02036853January 20145 February 2018An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency SyndromeAn Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome (GLUT1 DS)Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)Drug: TriheptanoinAdrian LacyUltragenyx Pharmaceutical IncRecruiting1 Year50 YearsAll50Phase 2United States
17NCT02014883December 201311 May 2015Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DSPhase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DSGlut1 Deficiency SyndromeDrug: GLUT1 DSInstitut National de la Santé Et de la Recherche Médicale, FranceUltragenyx Pharmaceutical IncRecruiting3 YearsN/ABoth20Phase 2France
18NCT02018315January 201219 February 2015Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D)Clinical Trial of Citric Acid Cycle Stimulation in Energy-deficiency States: Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D) (NMTUT 2010B)Glucose Transporter Type 1 Deficiency Syndrome;GLUT1 Deficiency SyndromeDrug: TriheptanoinJuan PascualNot recruiting1 Month20 YearsBoth14Phase 1United States

先頭へ